Trial Profile

A 52-Week Open-label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary)
Indications Neurodegenerative disorders; Psychotic disorders
Focus Adverse reactions
Sponsors Acadia Pharmaceuticals

Most Recent Events

01 Feb 2024 Status changed from active, no longer recruiting to completed.
16 Jun 2023 This trial has been completed in Czech Republic (Date of the global end of the trial: 05-May-2023), according to the European Clinical Trials Database record.
15 Jun 2023 This trial has been completed in Bulgaria (Date of the global end of the trial: 05-May-2023), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com